Literature DB >> 34155144

An epithelial Nfkb2 pathway exacerbates intestinal inflammation by supplementing latent RelA dimers to the canonical NF-κB module.

Meenakshi Chawla1, Tapas Mukherjee1, Alvina Deka1, Budhaditya Chatterjee1,2, Uday Aditya Sarkar1, Amit K Singh3, Saurabh Kedia3, Josephine Lum4, Manprit Kaur Dhillon4, Balaji Banoth1, Subhra K Biswas4, Vineet Ahuja3, Soumen Basak5.   

Abstract

Aberrant inflammation, such as that associated with inflammatory bowel disease (IBD), is fueled by the inordinate activity of RelA/NF-κB factors. As such, the canonical NF-κB module mediates controlled nuclear activation of RelA dimers from the latent cytoplasmic complexes. What provokes pathological RelA activity in the colitogenic gut remains unclear. The noncanonical NF-κB pathway typically promotes immune organogenesis involving Nfkb2 gene products. Because NF-κB pathways are intertwined, we asked whether noncanonical signaling aggravated inflammatory RelA activity. Our investigation revealed frequent engagement of the noncanonical pathway in human IBD. In a mouse model of experimental colitis, we established that Nfkb2-mediated regulations escalated the RelA-driven proinflammatory gene response in intestinal epithelial cells, exacerbating the infiltration of inflammatory cells and colon pathologies. Our mechanistic studies clarified that cell-autonomous Nfkb2 signaling supplemented latent NF-κB dimers, leading to a hyperactive canonical RelA response in the inflamed colon. In sum, the regulation of latent NF-κB dimers appears to link noncanonical Nfkb2 signaling to RelA-driven inflammatory pathologies and may provide for therapeutic targets.

Entities:  

Keywords:  NF-κB; Nfkb2; inflammatory bowel disease; intestinal inflammation; noncanonical

Mesh:

Substances:

Year:  2021        PMID: 34155144      PMCID: PMC8237674          DOI: 10.1073/pnas.2024828118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Type 3 Innate Lymphoid Cells Direct Goblet Cell Differentiation via the LT-LTβR Pathway during Listeria Infection.

Authors:  Yaya Pian; Qian Chai; Boyang Ren; Yue Wang; Mengjie Lv; Ju Qiu; Mingzhao Zhu
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 2.  The non-canonical NF-κB pathway in immunity and inflammation.

Authors:  Shao-Cong Sun
Journal:  Nat Rev Immunol       Date:  2017-06-05       Impact factor: 53.106

3.  Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.

Authors:  Brian Zarnegar; Soh Yamazaki; Jeannie Q He; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

4.  Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation.

Authors:  Kris A Steinbrecher; Eleana Harmel-Laws; Raquel Sitcheran; Albert S Baldwin
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

5.  How "humane" is your endpoint? Refining the science-driven approach for termination of animal studies of chronic infection.

Authors:  Nuno H Franco; Margarida Correia-Neves; I Anna S Olsson
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

6.  Experimental Models of Inflammatory Bowel Diseases.

Authors:  Patricia Kiesler; Ivan J Fuss; Warren Strober
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-03-01

7.  IκBβ enhances the generation of the low-affinity NFκB/RelA homodimer.

Authors:  Rachel Tsui; Jeffrey D Kearns; Candace Lynch; Don Vu; Kim A Ngo; Soumen Basak; Gourisankar Ghosh; Alexander Hoffmann
Journal:  Nat Commun       Date:  2015-05-07       Impact factor: 14.919

8.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

Review 9.  Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.

Authors:  Deenaz Zaidi; Eytan Wine
Journal:  Front Pediatr       Date:  2018-10-30       Impact factor: 3.418

10.  NF-κB1, NF-κB2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice.

Authors:  Michael D Burkitt; Abdalla F Hanedi; Carrie A Duckworth; Jonathan M Williams; Joseph M Tang; Lorraine A O'Reilly; Tracy L Putoczki; Steve Gerondakis; Rod Dimaline; Jorge H Caamano; D Mark Pritchard
Journal:  J Pathol       Date:  2015-04-21       Impact factor: 7.996

View more
  6 in total

1.  Duhuo Jisheng Decoction inhibits the activity of osteoclasts in osteonecrosis of the femoral head via regulation of the RELA/AKT1 axis.

Authors:  Tao Xing; Yongqiang Zhao; Jun Zhao; Zhenxing Jiang; Yingshuan Zhang; Shenghua Li
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 2.  NF-κB Inducing Kinase Regulates Intestinal Immunity and Homeostasis.

Authors:  Bingran Wang; Jun Shen
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 3.  NF-κB signaling in inflammation and cancer.

Authors:  Tao Zhang; Chao Ma; Zhiqiang Zhang; Huiyuan Zhang; Hongbo Hu
Journal:  MedComm (2020)       Date:  2021-12-16

Review 4.  Origin of the Functional Distinctiveness of NF-κB/p52.

Authors:  Gourisankar Ghosh; Vivien Ya-Fan Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-23

5.  Unusual Association of NF-κB Components in Tumor-Associated Macrophages (TAMs) Promotes HSPG2-Mediated Immune-Escaping Mechanism in Breast Cancer.

Authors:  Veronica De Paolis; Fabio Maiullari; Maila Chirivì; Marika Milan; Chiara Cordiglieri; Francesca Pagano; Alessandra Rita La Manna; Elena De Falco; Claudia Bearzi; Roberto Rizzi; Chiara Parisi
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

6.  TBX3 regulates the transcription of VEGFA to promote osteoblasts proliferation and microvascular regeneration.

Authors:  Lichuang Wu; Chenxian Su; Chuanhua Yang; Jinxing Liu; Yiheng Ye
Journal:  PeerJ       Date:  2022-07-11       Impact factor: 3.061

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.